Affiliation:
1. Department of Internal Medicine I, “V Babes” University of Medicine and Pharmacy, 300041 Timisoara, Romania
2. Department of Functional Sciences, “V Babes” University of Medicine and Pharmacy, 300041 Timisoara, Romania
3. Department of Anatomy and Embriology, “V Babes” University of Medicine and Pharmacy, 300041 Timisoara, Romania
Abstract
Sinusoidal obstruction syndrome/veno-occlusive disease (SOS/VOD) is a rare liver vascular condition, potentially life-threatening, with clinical signs of portal hypertension, frequently reported in relation to bone marrow transplantation and possibly in non-transplantation-related chemotherapy. We report the case of a 65-year-old female patient who insidiously developed fatigue, mild tenderness of the right upper abdominal quadrant, hepato-splenomegaly and slight weight gain consecutive to ascites development, as well as persistent elevation of transaminases and mild thrombocytopenia. To note, she had a previous history of colorectal cancer (CRC) with liver metastases and several courses of chemotherapy. Abdominal duplex and elastography measurements made the diagnosis of cirrhosis improbable. A lot of lab work-ups were performed in order to rule out several diseases and conditions. Further, transjugular access was used to perform the measurement of the hepatic venous pressure gradient and liver biopsy that confirmed SOS/VOD. In late 2023, she was diagnosed with endometrial adenocarcinoma, requiring chemotherapy again. At present, the liver condition is stationary, but the prognosis is, however, uncertain. In conclusion, we presented the atypical case of a female patient who developed portal hypertension syndrome associated with the late onset of SOS/VOD, after 5-fluorouracil and oxaliplatin chemotherapy for CRC and liver metastases, subsequently diagnosed with endometrial adenocarcinoma, which posed many diagnostic and therapeutic challenges. Given the potentially bad outcome, an early diagnosis of SOS/VOD in patients receiving drugs of risk is important not only to stratify further risk, but also to initiate an appropriate therapy in order to improve the prognosis.
Funder
“V Babeș” University of Medicine and Pharmacy, from Timisoara, Romania
Reference35 articles.
1. The portal hypertension syndrome: Etiology, classification, relevance, and animal models;Bosch;Hepatol. Int.,2018
2. An Anomalous Cause of Portal Hypertension;Brown;ACG Case Rep. J.,2021
3. Cirrhosis and portal hypertension: The importance of risk stratification, the role of hepatic venous pressure gradient measurement;Nicolini;World J. Hepatol.,2015
4. Berzigotti, A. (2017). Advances and challenges in cirrhosis and portal hypertension. BMC Med., 15.
5. Portal vein thrombosis and gut microbiota: Understanding the burden;Georgescu;Rev. Chim.,2019